There are 2934 resources available
Summary and close
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Welcome and introduction
Presenter: Thomas Powles
Session: Bristol-Myers Squibb - Long-term experience and survival: An overview of I-O therapy in RCC and future research in GU cancers
Resources:
Webcast
Welcome and introduction
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Keynote Lecture: An oncologist’s perspective on the melanoma treatment journey
Presenter: Michael Atkins
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
New data for the early treatment of melanoma
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
Early treatment interactive discussion and Q&A
Presenter: Eva Muñoz-Couselo
Session: Bristol Myers-Squibb - How immuno-oncology has changed the melanoma treatment landscape
Resources:
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant LBA54 and LBA55
Presenter: Ignacio Duran Martinez
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant 901O and 902O
Presenter: Yohann Loriot
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
1056 - Primary 2-year (yr) results of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Presenter: Reinhard Dummer
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast